Etid klinik pou Leukemi nan Tennessee
14 etid pou Leukemi ap chèche patisipan nan sit nan Tennessee.
Vil nan Tennessee
Tèks ofisyèl etid la (Anglè)
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
- Quetzal Site 12, Nashville
Ap rekriteFaz 3
Laj 18 a 71 · Tout sèks · Mizajou Sep 23, 2026 · NCT07504458A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia
- St. Jude Children's Research Hospital, Memphis
Ap rekriteFaz 1
Jiska laj 25 · Tout sèks · Mizajou Sep 15, 2026 · NCT06810583Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
- Sarah Cannon Research Institute, Nashville
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 28, 2026 · NCT07284433Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- Baptist Clinical Research Institute, Memphis
- Tennessee Oncology, Nashville
- TriStar Centennial Medical Center, Nashville
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 20, 2026 · NCT07007312Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Vanderbilt University Medical Center, Nashville
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 20, 2026 · NCT06001788Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- TriStar BMT, Nashville
Ap rekriteFaz 1/2
Laj 13 a 90 · Tout sèks · Mizajou Aug 6, 2026 · NCT06533579Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Vanderbilt University, Ingram Cancer Center, Nashville
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 7, 2026 · NCT07216443A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Vanderbilt University Medical Center, Nashville
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Apr 30, 2026 · NCT04256317The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- Baptist Clinical Research Institute, Memphis
Ap rekriteFaz 1/2
Laj 12 a 95 · Tout sèks · Mizajou Apr 15, 2026 · NCT04329728A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- TriStar Bone Marrow Transplant, Nashville
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Mar 13, 2026 · NCT05735184cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Baptist (BHMCC), Memphis
- Vanderbilt-Ingram Cancer Center, Nashville
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 40 ak plis · Tout sèks · Mizajou Jan 20, 2026 · NCT05366881SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Memphis
- Massive Bio SYNERGY-AI site, Nashville
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT03452774A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
- Sarah Cannon Research Institute, Nashville
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2025 · NCT06501196Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
- TriStar Bone Marrow Transplant, Nashville
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Nov 15, 2024 · NCT06034275Sous ClinicalTrials.gov, done yo ranmase Oct 3, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.